Deals: Page 82
-
Decisions, decisions: UCB to sell its generic unit to private equity firms
UCB is selling its U.S. generic division to Advent International and Avista Capital for $1.53 billion.
By Nicole Gray • Nov. 10, 2014 -
Isis Pharma wins $10M neurodegeneration treatment milestone from Biogen
The development deal between Biogen Idec and Isis Pharmaceuticals is bearing fruit as Isis begins clinical trials for its third drug for Biogen.
By Nicole Gray • Nov. 10, 2014 -
Political unrest in Russia nixes deal with German pharma company
Germany-based Fresenius has changed its mind about expanding its presence in Russia through a joint venture with Sistema JSFC thanks to ongoing tensions over Ukraine.
By Nicole Gray • Nov. 10, 2014 -
Salix Pharmaceuticals' inventory woes ruined potential Allergan buyout
A review of inventory revealed larger-than-communicated wholesaler supplies of Salix's top drug, Xifaxan (rifaximin), meaning sales will most likely be lower than anticipated.
By Nicole Gray • Nov. 10, 2014 -
This billionaire hedge fund manager may sue over busted AbbVie-Shire deal
Paul Singer is known to be litigious—and he isn't happy that the AbbVie-Shire merger fell through.
By Nicole Gray • Nov. 7, 2014 -
Allergan, Actavis talk merger while Valeant gets the cold shoulder
Can Allergan continue to stave off the persistent Valeant?
By Nicole Gray • Nov. 7, 2014 -
Largest US pharma benefits manager may seek alcohol/tobacco-free network
Express Scripts has been keeping a close eye on CVS Caremark's anti-tobacco crusade.
By Nicole Gray • Nov. 6, 2014 -
Bayer injects $25 million cash into biotech venture capital fund
The venture capital company, Versant Ventures, has now surpassed its $300 million funding goal thanks to Bayer.
By Nicole Gray • Nov. 4, 2014 -
Allergan-Valeant standoff rages on as Allergan loses in court
A judge refuses to issue an injunction against Valeant in response to Allergan's claim that the company violated securities laws. Now, Valeant is free to vote its shares and Allergan is weighing its options.
By Nicole Gray • Nov. 4, 2014 -
Could the Sanofi CEO's firing doom a $150 million inhaled insulin deal?
Viehbacher's boot could spell trouble for the partnership despite MannKind's assurances, according to one analyst.
By Sy Mukherjee • Nov. 4, 2014 -
Diagnostics giant LabCorp buys CRO Covance for $6.1 billion
LabCorp has been aggressively diversifying and consolidating its service offerings, and the Covance acquisition brings it into the clinical trial services arena.
By Nicole Gray • Nov. 4, 2014 -
Abbott acquires heart-mapping company Topera for $250 million
With its acquisition of CA-based Topera, Abbott isn't just adding to its large diagnostics franchise. It's entering the $3 billion global market for catheter-based electrophysiology.
By Nicole Gray • Oct. 31, 2014 -
Sacked Sanofi chief's golden parachute more like a bronze parachute
The former CEO of Sanofi, Chris Viehbacher, should be eligible for a $7.8 million exit fee—assuming that Sanofi achieved certain performance goals during the last three years.
By Nicole Gray • Oct. 31, 2014 -
With Viehbacher gone, who will be the next Sanofi chief?
Every team needs a leader, and Sanofi's board of directors knows that. The question is: who can offer the type of pharmaceutical company leadership—and communication style—the board wants?
By Nicole Gray • Oct. 30, 2014 -
Pfizer pulls the plug on pain deal with Pain Therapeutics
Investors felt the pain when Pfizer announced it won't be moving forward with an agreement to develop and commercialize an extended-release formulation of oxycodone.
By Nicole Gray • Oct. 28, 2014 -
Novartis sells off flu vaccines business to CSL for $275 million
This is it for Novartis and vaccines: After selling off most of its vaccines to GSK in April for $7.1 billion, the company has now sold the rest of its portfolio to Australia-based CSL for $275 million.
By Nicole Gray • Oct. 28, 2014 -
Roche to spend $3.2B on massive R&D cluster in Basel
The 10-year goal is to eventually move all Basel-based employees to this new mega-site.
By Nicole Gray • Oct. 28, 2014 -
Valeant poised to raise Allergan bid
The offer will provide "shareholder value" of at least $200/share, Valeant's CEO says in a letter riddled with tough talk.
By Randy Lilleston • Oct. 27, 2014 -
Actavis to cut more jobs, this time in New York
There are lay-offs scheduled for three facilities in New York as Actavis continued to integrate the recently-acquired Forest Labs into its business.
By Nicole Gray • Oct. 24, 2014 -
The $5.3B Mylan-Abbott inversion deal won't go the way of AbbVie-Shire
Mylan still plans to buy a portion of Abbott's overseas generics portfolio and relocate to the Netherlands. But some tweaks have been made to the deal—and it's unclear exactly why.
By Sy Mukherjee • Oct. 22, 2014 -
Actelion chief says it's time for pharma to ditch tax-inversion mergers
Actelion CEO Jean-Paul Clozel praises U.S. efforts to curb tax-inversions and says pharma companies should drop the gimmicks and pursue real value when cutting deals.
By Sy Mukherjee • Oct. 21, 2014 -
AbbVie-Shire deal effectively dead in the water
The Obama administration's renewed push to curb tax-inversion mergers claims its first victim.
By Sy Mukherjee • Oct. 16, 2014 -
Report: 6 US Ranbaxy execs head for the exits before Sun Pharma merger
“The core team of Ranbaxy in the U.S., which was running the show so far, resigned in one go last week," according to a company source.
By Sy Mukherjee • Oct. 13, 2014 -
Endo to buy Auxilium at a premium for $2.6 billion
Endo’s upcoming purchase of Auxilium will strengthen its already formidable men’s health franchise—and has stoked investor’s enthusiasm for Auxilum shares, which were up 10% on the news.
By Nicole Gray • Oct. 10, 2014 -
Here come the layoffs: Targacept-AstraZeneca R&D partnership nixed
After 10 years of focused R&D on an Alzheimer’s disease drug, Targacept and AstraZenenca have called it quits.
By Nicole Gray • Oct. 10, 2014
Previous
